Aeglea Bio Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AGLE Nasdaq 8731 https://www.aeglea.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aeglea Bio Therapeutics Inc

Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe - May 26th, 2022 3:18 pm
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study - May 25th, 2022 4:07 pm
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate - May 23rd, 2022 3:46 pm
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata - May 23rd, 2022 3:33 pm
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase - May 20th, 2022 1:50 pm
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate - May 18th, 2022 3:47 pm
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study - May 18th, 2022 3:03 pm
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement - May 17th, 2022 3:31 pm
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia - May 13th, 2022 2:30 pm
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs - May 11th, 2022 1:47 pm
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market - May 5th, 2022 1:28 pm
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates - May 5th, 2022 11:45 am
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates - May 5th, 2022 10:30 am
Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA - Apr 13th, 2022 4:42 pm
Aeglea's stock rises after asking the FDA to approve therapy for rare disorder - Apr 12th, 2022 12:10 pm
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency - Apr 12th, 2022 10:01 am
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD - Apr 11th, 2022 8:30 pm
Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022 - Apr 6th, 2022 11:59 am
Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting - Mar 29th, 2022 11:59 am
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates - Mar 8th, 2022 1:35 pm